Langdon B. Wheeler

Numeric Investors LLC is a SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Langdon Wheeler in 1989 as Numeric Investors LP. They are a wholly owned subsidiary of Man Investments Holdings, Inc., which is ultimately held by Man Group Plc (LON: EMG) in Great Britain. Numeric Investors provides investment advisory services for US and non-US taxable and tax-exempt clients, which are primarily institutions, that invest through separately managed accounts; however, the firm also provides investment advisory services to privately offered pooled investment funds they sponsored.

State Street Research & Management Company (SSR), with a history dating back to 1924, is one of the nation's first investment management organizations. The Boston-based firm is a subsidiary of MetLife (NYSE:MET), one of the world's largest financial services companies. The firm, together with its affiliate SSR Realty, actively manages stock, bond, balanced and real estate portfolios for both institutional and individual investors. SSR manages pension money for many of the largest U.S. corporate pension plans. SSR also manages money for public and union pension plans, foundations, endowments, and mutual funds.

Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA.

Part of Compagnie de Saint-Gobain SA, Chemfab Corp. is an emerging biotechnology company based in Merrimack, NH that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer. The company focuses on natural killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for chimeric antigen receptors (CAR) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. The company's initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma (HCC) and glioblastoma. HCC is a leading cause of cancer-related death, expected to cause 1 million deaths annually by 2030. Despite advances in immunotherapy, with current treatment options including multi-kinase inhibitors (TKI) and checkpoint inhibitors, life expectancy for patients diagnosed with HCC remains very low.